LYRA · As filed with the SEC
Lyra Therapeutics balance sheet, by quarter
The statement as Lyra Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 15,893,000 | 22,055,000 | 29,784,000 | 31,735,000 |
| Prepaid expenses and other current assets | 379,000 | 964,000 | 1,279,000 | 2,170,000 |
| Total current assets | 16,272,000 | 23,019,000 | 31,063,000 | 33,905,000 |
| Property and equipment, net | 1,051,000 | 1,122,000 | 1,159,000 | 1,276,000 |
| Operating lease right-of-use assets | 16,792,000 | 17,575,000 | 18,358,000 | 19,142,000 |
| Restricted cash | 1,993,000 | 1,993,000 | 1,993,000 | 1,993,000 |
| Total assets | 36,108,000 | 43,709,000 | 52,573,000 | 56,316,000 |
| Current liabilities: | ||||
| Accounts payable | 663,000 | 627,000 | 680,000 | 725,000 |
| Restructuring liability | 3,266,000 | 3,059,000 | 3,486,000 | 4,039,000 |
| Accrued expenses and other current liabilities | — | 1,103,000 | 2,413,000 | 2,247,000 |
| Accrued expenses and other current liabilities | 775,000 | — | — | — |
| Operating lease liabilities | 4,818,000 | 4,684,000 | 4,552,000 | 4,243,000 |
| Deferred revenue | — | 7,000 | 32,000 | 216,000 |
| Total current liabilities | 9,522,000 | 9,480,000 | 11,163,000 | 11,470,000 |
| Operating lease liabilities, net of current portion | 25,441,000 | 26,695,000 | 27,926,000 | 29,113,000 |
| Deferred revenue, net of current portion | 11,862,000 | 11,862,000 | 11,862,000 | 11,861,000 |
| Total liabilities | 46,825,000 | 48,037,000 | 50,951,000 | 52,444,000 |
| Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2025 and 2024; 1,774,882 and 1,310,308 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 2,000 | 2,000 | 2,000 | 66,000 |
| Additional paid-in capital | 422,990,000 | 422,428,000 | 422,394,000 | 417,143,000 |
| Accumulated deficit | (433,709,000) | (426,758,000) | (420,774,000) | (413,337,000) |
| Total stockholders' (deficit) equity | (10,717,000) | (4,328,000) | 1,622,000 | 3,872,000 |
| Total liabilities and stockholders' (deficit) equity | 36,108,000 | 43,709,000 | 52,573,000 | 56,316,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.